Pathology, University of Cambridge, Cambridge, United Kingdom.
Gynecologic Oncology, Medical University Vienna, Vienna, Austria.
Vaccine. 2021 Apr 15;39(16):2214-2223. doi: 10.1016/j.vaccine.2021.01.060. Epub 2021 Feb 28.
Studies on the cross-protective effect of HPV bivalent and quadrivalent vaccines demonstrated inconsistent findings against additional HPV types covered by the nonavalent vaccine. The objective of this study was to conduct a systematic literature review to assess the consistency and durability of the cross-protective neutralizing antibody immune responses of the currently licensed bivalent and quadrivalent vaccines to non-vaccine HPV types targeted by the nonavalent vaccine (HPV 6, 11, 31, 33, 45, 52, and 58).
PubMed and EMBASE databases were searched from 2008 to 2019 to identify studies reporting antibody/immune response after vaccination with either the bivalent, quadrivalent, or nonavalent vaccine. Key outcomes were seroconversion, seropositivity or geometric mean titers against HPV types 6, 11, 31, 33, 45, 52, and 58.
Eighteen publications met inclusion criteria, reporting on 14 interventional and five observational studies. Across all studies, immune responses to non-vaccine high-risk HPV types after bivalent vaccination were higher than baseline or quadrivalent vaccine. Nonavalent vaccine elicited near total seroconversion to HPV types 31, 33, 45, 52, and 58, with seropositivity remaining near 100% up to 24 months post-dose 1. In contrast, bivalent and quadrivalent vaccination resulted in lower seroconversion levels for non-vaccine types, which waned over time.
The cross-protection antibody/immune response among participants having received all three doses of bivalent or quadrivalent vaccine is not comparable to the specific response elicited by HPV vaccine types. Even in cases where a statistically significant cross-reactive immunological response is reported, long-term data on the duration of the response beyond two years are very limited. Further, the lack of a standard for assays limits comparability of results between studies.
针对 HPV 二价和四价疫苗的交叉保护作用的研究结果显示,针对非九价疫苗涵盖的其他 HPV 型别,其结果并不一致。本研究的目的是进行系统文献回顾,以评估目前已获许可的二价和四价疫苗对非九价疫苗(HPV 6、11、31、33、45、52 和 58)针对的非疫苗型 HPV 型别的交叉保护中和抗体免疫应答的一致性和持久性。
从 2008 年至 2019 年,检索 PubMed 和 EMBASE 数据库,以确定报告接种二价、四价或九价疫苗后抗体/免疫应答的研究。主要结局指标为针对 HPV 6、11、31、33、45、52 和 58 型的血清转化率、血清阳性率或几何平均滴度。
18 篇文献符合纳入标准,报告了 14 项干预性研究和 5 项观察性研究。在所有研究中,与基线或四价疫苗相比,二价疫苗接种后对非疫苗高危型 HPV 型别的免疫应答更高。九价疫苗接种后,针对 HPV 31、33、45、52 和 58 型几乎完全产生血清转化,在接种第 1 剂后 24 个月内,血清阳性率仍接近 100%。相比之下,二价和四价疫苗接种后,非疫苗型的血清转化率较低,且随着时间的推移逐渐减弱。
接受二价或四价疫苗全部三剂接种的参与者的交叉保护抗体/免疫应答与 HPV 疫苗型别引起的特定应答不可比。即使报告了具有统计学意义的交叉反应性免疫应答,关于两年后应答持续时间的长期数据也非常有限。此外,缺乏检测标准限制了研究之间结果的可比性。